Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
60.6M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
11.8M
-
Shares change
-
+133K
-
Total reported value, excl. options
-
$115M
-
Value change
-
+$3.89M
-
Number of buys
-
20
-
Number of sells
-
-16
-
Price
-
$9.71
Significant Holders of Immuneering Corp - Class A Common Stock (IMRX) as of Q1 2023
38 filings reported holding IMRX - Immuneering Corp - Class A Common Stock as of Q1 2023.
Immuneering Corp - Class A Common Stock (IMRX) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.8M shares
of 60.6M outstanding shares and own 19.51% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (3.46M shares), Cormorant Asset Management, LP (2.39M shares), CITADEL ADVISORS LLC (2.1M shares), BlackRock Inc. (1.34M shares), VANGUARD GROUP INC (876K shares), FMR LLC (403K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (205K shares), GEODE CAPITAL MANAGEMENT, LLC (169K shares), TD Asset Management Inc (144K shares), and MILLENNIUM MANAGEMENT LLC (98.8K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.